Raffles Medical Group Ltd (SGX:BSL)
Singapore · Delayed Price · Currency is SGD 0.8800
-0.0050 (-0.56%)
Aug 6, 2026, 9:09 AM SGT
Raffles Medical Group Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 740.04 | 765.3 | 751.56 | 706.92 | 822.92 | 723.79 |
Other Revenue | 0.27 | 0.27 | 0.86 | 1.12 | 2.03 | 1.44 |
| 740.31 | 765.57 | 752.43 | 708.04 | 824.95 | 725.23 | |
Revenue Growth | -3.30% | 1.75% | 6.27% | -14.17% | 13.75% | 27.64% |
Cost of Revenue | 411.99 | 418.26 | 413.39 | 392.1 | 424.85 | 530.24 |
Gross Profit | 328.32 | 347.31 | 339.03 | 315.94 | 400.1 | 194.99 |
Selling, General & Admin | 159.88 | 168.56 | 168.47 | 138.31 | 109.2 | 5.44 |
Amortization of Goodwill & Intangibles | 1.32 | 1.57 | 1.55 | 1.53 | 1.93 | 2.6 |
Other Operating Expenses | 39.08 | 46.19 | 42.33 | 32 | 41.22 | 34.22 |
Operating Expenses | 245.84 | 261.33 | 253.94 | 207.76 | 186.83 | 76.79 |
Operating Income | 82.48 | 85.97 | 85.1 | 108.19 | 213.26 | 118.2 |
Interest Expense | -3.05 | -4.09 | -5.78 | -6.08 | -6.85 | -6.36 |
Interest & Investment Income | 5.02 | 7.33 | 10.25 | 9.76 | 2.74 | 0.63 |
EBT Excluding Unusual Items | 84.45 | 89.21 | 89.56 | 111.87 | 209.15 | 112.48 |
Impairment of Goodwill | -0.32 | -0.32 | -2.6 | - | -5.87 | -3.78 |
Asset Writedown | 4.7 | 4.7 | -0 | 7.4 | -12.03 | 0.41 |
Other Unusual Items | - | - | - | 0.17 | 0.08 | 6.47 |
Pretax Income | 88.84 | 93.59 | 86.96 | 119.44 | 191.34 | 115.58 |
Income Tax Expense | 20.94 | 22.52 | 24.68 | 28.35 | 47.94 | 31.87 |
Earnings From Continuing Operations | 67.9 | 71.07 | 62.28 | 91.09 | 143.4 | 83.72 |
Minority Interest in Earnings | -0.42 | -0.5 | -0.04 | -0.94 | -0.19 | 0.46 |
Net Income | 67.48 | 70.57 | 62.24 | 90.15 | 143.21 | 84.17 |
Net Income to Common | 67.48 | 70.57 | 62.24 | 90.15 | 143.21 | 84.17 |
Net Income Growth | -4.38% | 13.38% | -30.96% | -37.05% | 70.15% | 27.74% |
Shares Outstanding (Basic) | 1,843 | 1,850 | 1,857 | 1,859 | 1,857 | 1,868 |
Shares Outstanding (Diluted) | 1,847 | 1,854 | 1,861 | 1,869 | 1,866 | 1,876 |
Shares Change | -0.35% | -0.36% | -0.41% | 0.12% | -0.54% | 1.96% |
EPS (Basic) | 0.04 | 0.04 | 0.03 | 0.05 | 0.08 | 0.05 |
EPS (Diluted) | 0.04 | 0.04 | 0.03 | 0.05 | 0.08 | 0.04 |
EPS Growth | -4.16% | 14.07% | -30.70% | -37.16% | 70.82% | 25.42% |
Free Cash Flow | 101.22 | 93.46 | 66.98 | 168.79 | 171.21 | 110.17 |
Free Cash Flow Per Share | 0.06 | 0.05 | 0.04 | 0.09 | 0.09 | 0.06 |
Dividend Per Share | 0.030 | 0.030 | 0.025 | 0.024 | 0.038 | 0.018 |
Dividend Growth | 0% | 20.00% | 4.17% | -36.84% | 111.11% | -28.00% |
Gross Margin | 44.35% | 45.37% | 45.06% | 44.62% | 48.50% | 26.89% |
Operating Margin | 11.14% | 11.23% | 11.31% | 15.28% | 25.85% | 16.30% |
Profit Margin | 9.12% | 9.22% | 8.27% | 12.73% | 17.36% | 11.61% |
Free Cash Flow Margin | 13.67% | 12.21% | 8.90% | 23.84% | 20.75% | 15.19% |
EBITDA | 112.31 | 116.75 | 115.1 | 132.9 | 239.72 | 143.3 |
EBITDA Margin | 15.17% | 15.25% | 15.30% | 18.77% | 29.06% | 19.76% |
D&A For EBITDA | 29.82 | 30.77 | 30.01 | 24.71 | 26.46 | 25.1 |
EBIT | 82.48 | 85.97 | 85.1 | 108.19 | 213.26 | 118.2 |
EBIT Margin | 11.14% | 11.23% | 11.31% | 15.28% | 25.85% | 16.30% |
Effective Tax Rate | 23.57% | 24.07% | 28.38% | 23.73% | 25.05% | 27.57% |